These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19287973)

  • 1. Combination therapy using three novel prolactin receptor antagonist-based fusion proteins effectively inhibits tumor recurrence and metastasis in HER2/neu transgenic mice.
    Tomblyn S; Springs AE; Langenheim JF; Chen WY
    Int J Oncol; 2009 Apr; 34(4):1139-46. PubMed ID: 19287973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer.
    Xu C; Langenheim JF; Chen WY
    Breast Cancer Res Treat; 2012 Jul; 134(1):157-69. PubMed ID: 22270933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
    Beck MT; Chen NY; Franek KJ; Chen WY
    Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
    Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
    Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.
    Campbell MJ; Wollish WS; Lobo M; Esserman LJ
    In Vitro Cell Dev Biol Anim; 2002 Jun; 38(6):326-33. PubMed ID: 12513120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.
    Langenheim JF; Chen WY
    Breast Cancer Res Treat; 2005 Apr; 90(3):281-93. PubMed ID: 15830142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer.
    Dankort D; Maslikowski B; Warner N; Kanno N; Kim H; Wang Z; Moran MF; Oshima RG; Cardiff RD; Muller WJ
    Mol Cell Biol; 2001 Mar; 21(5):1540-51. PubMed ID: 11238891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
    Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E
    Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of Her2/Neu mammary tumor development in mda-7/IL-24 transgenic mice.
    Li YJ; Liu G; Xia L; Xiao X; Liu JC; Menezes ME; Das SK; Emdad L; Sarkar D; Fisher PB; Archer MC; Zacksenhaus E; Ben-David Y
    Oncotarget; 2015 Nov; 6(35):36943-54. PubMed ID: 26460950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fusion between cancer cells and macrophages occurs in a murine model of spontaneous neu+ breast cancer without increasing its metastatic potential.
    Lizier M; Anselmo A; Mantero S; Ficara F; Paulis M; Vezzoni P; Lucchini F; Pacchiana G
    Oncotarget; 2016 Sep; 7(38):60793-60806. PubMed ID: 27563823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel design of targeted endocrine and cytokine therapy for breast cancer.
    Zhang G; Li W; Holle L; Chen N; Chen WY
    Clin Cancer Res; 2002 Apr; 8(4):1196-205. PubMed ID: 11948133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.
    Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Cavallo F; Pupa SM; Rossi I; Colombo MP; Ricci C; Astolfi A; Musiani P; Forni G; Lollini PL
    J Exp Med; 2001 Nov; 194(9):1195-205. PubMed ID: 11696586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice.
    Tomblyn S; Langenheim JF; Jacquemart IC; Holle E; Chen WY
    Int J Oncol; 2005 Nov; 27(5):1381-9. PubMed ID: 16211235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.
    Eralp Y; Wang X; Wang JP; Maughan MF; Polo JM; Lachman LB
    Breast Cancer Res; 2004; 6(4):R275-83. PubMed ID: 15217493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
    Jabrane-Ferrat N; Campbell MJ; Esserman LJ; Peterlin BM
    Cancer Gene Ther; 2006 Nov; 13(11):1002-10. PubMed ID: 16841083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice.
    Finkle D; Quan ZR; Asghari V; Kloss J; Ghaboosi N; Mai E; Wong WL; Hollingshead P; Schwall R; Koeppen H; Erickson S
    Clin Cancer Res; 2004 Apr; 10(7):2499-511. PubMed ID: 15073130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
    Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
    Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimetastatic activity of a preventive cancer vaccine.
    Nanni P; Nicoletti G; Palladini A; Croci S; Murgo A; Antognoli A; Landuzzi L; Fabbi M; Ferrini S; Musiani P; Iezzi M; De Giovanni C; Lollini PL
    Cancer Res; 2007 Nov; 67(22):11037-44. PubMed ID: 18006850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice.
    Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL
    Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.